ATE414529T1 - Zusammensetzungen zur behandlung von beeinträchtigten zwischenmenschlischen störungen und verhaltenstörungen - Google Patents

Zusammensetzungen zur behandlung von beeinträchtigten zwischenmenschlischen störungen und verhaltenstörungen

Info

Publication number
ATE414529T1
ATE414529T1 AT05006494T AT05006494T ATE414529T1 AT E414529 T1 ATE414529 T1 AT E414529T1 AT 05006494 T AT05006494 T AT 05006494T AT 05006494 T AT05006494 T AT 05006494T AT E414529 T1 ATE414529 T1 AT E414529T1
Authority
AT
Austria
Prior art keywords
disorders
compositions
treatment
environment
interpersonal
Prior art date
Application number
AT05006494T
Other languages
English (en)
Inventor
Tony Marcel
Francois Rougeon
Catherine Rougeot
Original Assignee
Pasteur Institut
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Centre Nat Rech Scient filed Critical Pasteur Institut
Application granted granted Critical
Publication of ATE414529T1 publication Critical patent/ATE414529T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Radiation-Therapy Devices (AREA)
AT05006494T 1999-06-23 2000-06-22 Zusammensetzungen zur behandlung von beeinträchtigten zwischenmenschlischen störungen und verhaltenstörungen ATE414529T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14056399P 1999-06-23 1999-06-23

Publications (1)

Publication Number Publication Date
ATE414529T1 true ATE414529T1 (de) 2008-12-15

Family

ID=22491816

Family Applications (2)

Application Number Title Priority Date Filing Date
AT05006494T ATE414529T1 (de) 1999-06-23 2000-06-22 Zusammensetzungen zur behandlung von beeinträchtigten zwischenmenschlischen störungen und verhaltenstörungen
AT00947924T ATE291927T1 (de) 1999-06-23 2000-06-22 Peptide zur behandlung von beeinträchtigten zwischenmenschlischen störungen und verhaltenstörungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT00947924T ATE291927T1 (de) 1999-06-23 2000-06-22 Peptide zur behandlung von beeinträchtigten zwischenmenschlischen störungen und verhaltenstörungen

Country Status (14)

Country Link
US (2) US7387778B2 (de)
EP (2) EP1593387B1 (de)
JP (1) JP2003512302A (de)
CN (1) CN1189211C (de)
AT (2) ATE414529T1 (de)
AU (1) AU6154700A (de)
CA (1) CA2376935A1 (de)
CY (1) CY1108745T1 (de)
DE (2) DE60040878D1 (de)
DK (2) DK1593387T3 (de)
ES (2) ES2238299T3 (de)
NZ (1) NZ516477A (de)
PT (2) PT1185294E (de)
WO (1) WO2001000221A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6589750B2 (en) * 1997-02-20 2003-07-08 Institut Pasteur Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives
CA2376935A1 (en) 1999-06-23 2001-01-04 Institut Pasteur Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders
PT1216707E (pt) * 2000-12-22 2005-06-30 Pasteur Institut Novas utilizacoes terapeuticas para um smr-1-peptideo
EP1911763B1 (de) 2003-01-28 2010-08-11 Ironwood Pharmaceuticals, Inc. Zusammensetzungen zur Behandlung von Magen-Darm-Störungen
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
HUE016435T4 (en) 2004-03-19 2017-01-30 Pasteur Institut Peptides derived from human BPLP protein, polynucleotides encoding peptides, and antibodies to peptides
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8889827B2 (en) 2008-04-07 2014-11-18 Institut Pasteur Opiorphin peptide derivatives as potent inhibitors of enkephalin-degrading ectopeptidases
FR2931362B1 (fr) 2008-05-26 2017-08-18 Pasteur Institut L'opiorphine pour une utilisation en tant que psychostimulant.
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
CA2645452A1 (en) * 2008-11-28 2010-05-28 Institut Pasteur Use of basic prolin-rich lacrimal gene products, such as opiorphin, as a biomarker
US20100221329A1 (en) 2008-12-03 2010-09-02 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase c agonists and methods of use
DE102009039655B3 (de) 2009-09-02 2011-03-31 ITT Mfg. Enterprises, Inc., Wilmington UV-Desinfektionseinrichtung für Abwasser und Trinkwasser mit einer Reinigungsvorrichtung
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
DK2681236T3 (en) 2011-03-01 2018-04-16 Synergy Pharmaceuticals Inc PROCEDURE FOR MANUFACTURING GUANYLATE CYCLASE-C-AGONISTS
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
BR112015030326A2 (pt) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
GB201607814D0 (en) 2016-05-04 2016-06-15 5D Health Prot Group Ltd Anti-microbial compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8327966D0 (en) * 1983-10-19 1983-11-23 Nyegaard & Co As Chemical compounds
FR2637600B1 (fr) * 1988-10-11 1992-03-06 Pasteur Institut Peptides et polypeptides provenant de la glande sous maxillaire du rat, anticorps monoclonaux et polyclonaux correspondants, hybridomes correspondants et applications de ces produits au diagnostic, a la detection ou a des fins therapeutiques
US5589189A (en) * 1994-09-14 1996-12-31 Nexstar Pharmaceuticals, Inc. Liposome dispersion
US6589750B2 (en) * 1997-02-20 2003-07-08 Institut Pasteur Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives
KR100353014B1 (ko) 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
US6455564B1 (en) * 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
CA2376935A1 (en) 1999-06-23 2001-01-04 Institut Pasteur Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders
PT1216707E (pt) 2000-12-22 2005-06-30 Pasteur Institut Novas utilizacoes terapeuticas para um smr-1-peptideo

Also Published As

Publication number Publication date
EP1593387B1 (de) 2008-11-19
US20030078200A1 (en) 2003-04-24
CN1356906A (zh) 2002-07-03
JP2003512302A (ja) 2003-04-02
DE60019106T2 (de) 2006-02-16
PT1593387E (pt) 2009-03-18
PT1185294E (pt) 2005-08-31
US7387778B2 (en) 2008-06-17
AU6154700A (en) 2001-01-31
ES2315753T3 (es) 2009-04-01
ATE291927T1 (de) 2005-04-15
EP1593387A1 (de) 2005-11-09
WO2001000221A2 (en) 2001-01-04
US20030186870A1 (en) 2003-10-02
DE60019106D1 (de) 2005-05-04
CY1108745T1 (el) 2014-04-09
CA2376935A1 (en) 2001-01-04
EP1185294B1 (de) 2005-03-30
NZ516477A (en) 2004-02-27
CN1189211C (zh) 2005-02-16
ES2238299T3 (es) 2005-09-01
WO2001000221A3 (en) 2001-05-03
DK1185294T3 (da) 2005-08-01
EP1185294A2 (de) 2002-03-13
DE60040878D1 (de) 2009-01-02
DK1593387T3 (da) 2009-03-02

Similar Documents

Publication Publication Date Title
CY1108745T1 (el) Πεπτιδια δια τη θεραπευτικη αγωγη κακης συμπεριφορας μεταξυ προσωπων
ATE430193T1 (de) Rekombinante alpha-l-iduronidase und behandlung von durch diese hervorgerufene mangelerkrankungen
SE9803710D0 (sv) Use of certain drugs for treating nerve root injury
ATE492279T1 (de) Bupropinmetaboliten zur behandlung von dementia und anderen zerebrovasckulären erkrankungen
ATE325612T1 (de) Verwendung von hydroxyethylrutosiden zur behandlung von erkältungssymptomen, symptomen der allergischen rhinitis und atemwegsinfektionen
ATE510542T1 (de) Noribogain zur behandlung von schmerzen und drogenabhängigkeit
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
DE60026627D1 (de) Reboxetin zur Behandlung von Fibromyalgie und anderen somatoformen Störungen
DE60333857D1 (de) Oxytocin zur Behandlung von Autismus und Asperger-Syndrom
WO2005020928A3 (en) Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
BR0015698A (pt) Composições e métodos para tratamento de doenças alérgicas
DE60008753D1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
IL163026A (en) Benzofuran and benzothiophene derivatives useful in the treatment of hyper-proliferative disorders
ATE355054T1 (de) Verfahren und verbindungen zur behandlung der depression
ATE296098T1 (de) Verwendung von topiramat zur behandlung und diagnostizierung von atemstörungen während des schlafens und mittel zur durchführung der behandlung und diagnose
DE602004028574D1 (de) Zusammensetzungen und verfahren zur behandlung des reizdarmsyndroms und von nichtulzeröser dyspepsie
ATE541565T1 (de) Topische verwendung von muskarinischen und opioiden mitteln zur behandlung von tinnitus
DE60018704D1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
MXPA04010816A (es) Acidos aminoalcanfosfonicos sustituidos para el tratamiento de dolor neuropatico, trastornos afectivos y de la atencion, esquizofrenia, tinitus, miopia y otros trastornos oculares.
ATE369143T1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
ATE498397T1 (de) Verwendung von isorhamnetin zur behandlung von depressiven verstimmungen und erkrankungen
DE60108241D1 (de) Felabamat-derivate zur behandlung von neuropathischem schmerz
DE60137506D1 (de) Verwendung von polysulfatierten cyclodextrinen zur behandlung von arthrose
IL189190A0 (en) Use of fluorinated triazoles for treating pain and affective or attention disorders
DE112004002133D2 (de) Mittel und Verfahren zur Behandlung und Prävention von TSE sowie Verfahren zur Herstellung des Mittels

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1593387

Country of ref document: EP